Ensuring Optimal Patient Outcomes in the Treatment and Management of Atopic Dermatitis in the Infant and Pediatric Population

View Activity


Elaine Siegfried, MD
Division Director and Professor of Pediatrics and Dermatology
St. Louis University
St. Louis, MO

Marcia Hogeling, MD
Health Sciences Assistant Clinical Professor
Director of Pediatric Dermatology
Ronald Reagan UCLA Medical Center
Santa Monica, CA

President-Elect, American Headache Society


This case-based enduring activity will cover the treatment, and management of Atopic Dermatitis in the Infant and Pediatric Population


This activity is intended for US-based general pediatricians, internal medicine, and family physicians who are involved in the care and treatment of patients with AD.


After completing the CME activity, learners should be better able to:

  • Describe the impact of AD on physical, social, emotional, and mental aspects of patients’ lives throughout their lifespan
  • Discuss best practices for achieving a timely and accurate diagnosis of AD in patients of all ages in order to initiate appropriate treatment
  • Review the mechanisms of action and clinical profiles of current and emerging treatments for AD in infants, pediatric, adolescent, and adult patients


Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.


Med Learning Group designates this web-based activity for a maximum of 2.0 AMA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.


Purpose: This program would be beneficial for nurses involved in the care and treatment of patients with AD. CNE Credits: 2.0 ANCC Contact Hours.


Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 2.0 contact hours of continuing nursing education of RNs and APNs.


Elaine Siegfried, MD is a consultant for Regeneron, Sanofi Genzyme, UCB, AbbVie, Verrica, Leo, Novan, Pfizer, Pierre Fabre. Dr. Siegfried receives fees to SSM/SLU related to sponsoring clinical trials for Regeneron, Janssen, Lilly, Pierre Fabre, and Verrica. She receives grant funding supporting pediatric dermatology fellowship participants (2020-2022). Dr. Siegfried has received honoraria from Regeneron, Sanofi Genzyme, and Verrica; and is on the Data Safety Monitoring Board for UCB, Leo, Novan, and Pfizer.

Marcia Hogeling, MD, is a principal investigator in a Celgene study; funds are distributed to UCLA.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Nicole Longo, DO, FACOI, Director, Medical and Scientific Services for Med Learning Group, has nothing to disclose.
Ana Maria Albino, Program Manager for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.


Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.


There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures;
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.

You will receive your certificate as a downloadable file.


Med Learning Group makes every effort to develop CME activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

RELEASE DATE: July 13, 2020

EXPIRATION DATE: July 13, 2021


Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at info@medlearninggroup.com

View Activity

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.